Skip to content
Screener

Niagen Bioscience NAGE Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$34.0MBeat by $2.9M
EPS$0.05Beat by $0.04
Revenue estimate$31.1M
EPS estimate$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q3 2025

Income statement

See full
Revenue$34.0M+32.9%
Gross profit$21.9M+35.0%
Operating income$4.2M+164%
Net income$4.6M+144%
EPS (diluted)$0.05+150%

Balance sheet

See full
Cash & equivalents$64.3M+98.4%
Total debt$3.1M+5.5%
Total equity$70.7M+106%
Total assets$98.1M+73.6%

Cash flow

See full
Operating cash flow$3.7M+5.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$744.1M—
Enterprise value$682.86M—
P/E36.4×—
P/S6×—

Profitability

See full
Gross margin63.9%+2.4pp
Operating margin15.5%+15.0pp
Net margin16.4%+14.9pp

Returns & leverage

See full
Return on equity38.9%+34.4pp
Debt / equity0×0.0×
Current ratio4.1×+1.2×

Segments

By segment

See full
Consumer Products segment$26.0M+43.6%
Ingredients segment$7.2M+7.9%
Analytical Reference Standards and Services segment$772.0K-1.5%

FAQ

When did Niagen Bioscience report Q3 2025 earnings?
Niagen Bioscience (NAGE) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Niagen Bioscience's Q3 2025 revenue and EPS?
Niagen Bioscience reported revenue of $34.0M and eps of $0.05 for Q3 2025.
Did Niagen Bioscience beat estimates in Q3 2025?
Revenue beat the consensus estimate of $31.1M by $2.9M. EPS beat the consensus estimate of $0.01 by $0.04.
How did Niagen Bioscience's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 32.9% from $25.6M a year earlier and eps grew 150.0% from $0.02.
Where can I find Niagen Bioscience's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001386570-25-000021) and the 10-Q periodic report (0001386570-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.